R&D News | pharmaphorum

News

GSK bows to Trump pressure and pauses diversity policies

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.

News

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.

News

Scientists in a boat graphic from Owkin for ATLANTIS

Owkin launches ATLANTIS patient data mining project

Owkin has partnered 20 healthcare institutions on a patient data mining project, ATLANTIS, across oncology, immunology/inflammation, and neurology.

News

Eikon Therapeutics chief executive Roger Perlmutter

Perlmutter's Eikon raises $351m in major financing round

Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.

News

Bayer reveals phase 3 data for improved MRI contrast agent

Bayer is close to filing a new MRI contrast agent that can reduce levels of gadolinium, which can have health and environmental consequences.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

GSK bows to Trump pressure and pauses diversity policies

AbbVie pays Gubra $350m upfront to enter obesity field

Owkin launches ATLANTIS patient data mining project

Perlmutter's Eikon raises $351m in major financing round

Bayer reveals phase 3 data for improved MRI contrast agent

Data cues up AZ oral SERD filing in first-line breast cancer

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks